KANSAS CITY, Mo.--(BUSINESS WIRE)--Cerner Corp. (Nasdaq: CERN) announced today that Cerner Bridge™ Transfusion Administration and Specimen Collections software solution has received U.S. Food and Drug Administration (FDA) 510(k) pre-market notification clearance. Cerner will immediately make this solution available to clients.
